Novo Nordisk
NVO
NZ$123.39
Share price
-3.48%
Change (1 day)
-46.05%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Novo Nordisk (NVO) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : NZ$84.42 Billion
According to Novo Nordisk's latest financial reports the company's total liabilities are NZ$84.42 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Novo Nordisk - Total liabilities on balance sheet (from 2001 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | NZ$79.74 B | 63.76% |
| 2023-12-31 | NZ$48.69 B | 36.07% |
| 2022-12-31 | NZ$35.78 B | 29.72% |
| 2021-12-31 | NZ$27.58 B | 47.57% |
| 2020-12-31 | NZ$18.69 B | 23.45% |
| 2019-12-31 | NZ$15.14 B | 12.5% |
| 2018-12-31 | NZ$13.46 B | 12.86% |
| 2017-12-31 | NZ$11.92 B | 11.63% |
| 2016-12-31 | NZ$10.68 B | 11.31% |
| 2015-12-31 | NZ$9.59 B | 25.24% |
| 2014-12-31 | NZ$7.66 B | 22.51% |
| 2013-12-31 | NZ$6.25 B | 15.93% |
| 2012-12-31 | NZ$5.39 B | -11.28% |
| 2011-12-31 | NZ$6.08 B | 7.6% |
| 2010-12-31 | NZ$5.65 B | 12.13% |
| 2009-12-31 | NZ$5.04 B | -11.82% |
| 2008-12-31 | NZ$5.71 B | 43.7% |
| 2007-12-31 | NZ$3.97 B | 8.51% |
| 2006-12-31 | NZ$3.66 B | 10.65% |
| 2005-12-31 | NZ$3.31 B | 17.98% |
| 2004-12-31 | NZ$2.80 B | 17.4% |
| 2003-12-31 | NZ$2.39 B | -5.36% |
| 2002-12-31 | NZ$2.52 B | -22.38% |
| 2001-12-31 | NZ$3.25 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | NZ$194.84 B | 130.78% | 🇺🇸 USA |
 Eli Lilly LLY | NZ$122.06 B | 44.58% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$124.45 B | 47.40% | 🇺🇸 USA |
 Sanofi SNY | NZ$103.25 B | 22.30% | 🇫🇷 France |